Targeting ZIP12 with the monoclonal antibody APL-9796 reduces pulmonary hypertension symptoms in rodent models and shows promise as a therapy for PAH.
Pulmonary Hypertension Research and Treatments
Moving in Circulation, New England Journal of Medicine, Environmental research, Frontiers in Genetics, medRxiv and Science Translational Medicine.
- Moved, week to 23 Oct 2026
- 0
- Papers in 60 days
- 8
Rebuilt
Moved this week
Nothing in this topic has moved yet this week.
Latest in Pulmonary Hypertension Research and Treatments
Newest first · last 60 days
Transcatheter tricuspid-valve repair significantly improves outcomes in patients with severe tricuspid regurgitation, with a win ratio of 2.42 favoring repair at 1 year.
S1PR1, CA2, and ABCG2 are identified as potential diagnostic biomarkers for pulmonary arterial hypertension, with S1PR1 showing a protective role in endothelial cells.
- Open access
Sotatercept reduces right ventricular contractility by 24 weeks in pulmonary arterial hypertension patients but maintains RV-PA coupling and improves overall right heart mechanics.
Pulmonary-artery denervation reduces clinical worsening by nearly 50% in patients with heart failure-related pulmonary hypertension compared to medical therapy alone.
Browse JClub
Journals this month
- bioRxiv6183
- medRxiv1716
- PNAS472
- Sci Adv398
- JAMA274
- Environ Res230
- BMJ200
- Nat Commun171
- Environ Pollution165
- Nature161
- NEJM146
- Science141
- Lancet132
- Cell Rep130
- Curr Biol108
- J Exp Bot108
- mBio107
- Plant Cell Environ107
Topics moving, week to 23 Oct 2026
- Single-cell and spatial transcriptomics6
- Neuroinflammation and Neurodegeneration Mechanisms5
- Bacteriophages and microbial interactions5
- Gut microbiota and health5
- Genomics and Phylogenetic Studies4
- Cancer Genomics and Diagnostics4
- Cancer Immunotherapy and Biomarkers4
- Alzheimer's disease research and treatments3
- Inflammatory Bowel Disease3
- Influenza Virus Research Studies3
